NCIt related terms : Docetaxel and Trastuzumab (TH); Docetaxel and Trastuzumab-qyyp (TH); T-H (Docetaxel) (trastuzumab-pkrb); Docetaxel and Trastuzumab-herw (TH); T-H (Docetaxel) (trastuzumab-herw); Docetaxel and Trastuzumab-dttb (TH); T-H (Docetaxel) (trastuzumab-zerc); Docetaxel and Trastuzumab-anns (TH); Docetaxel and Trastuzumab-pkrb (TH); T-H (Docetaxel) (trastuzumab-anns); T-H (Docetaxel) (trastuzumab-dttb); T-H (Docetaxel); T-H (Docetaxel) (trastuzumab-qyyp); T-H (Docetaxel) (trastuzumab-dkst); Docetaxel and Trastuzumab-zerc (TH); Docetaxel and Trastuzumab-dkst (TH);
NCIt definition : A regimen consisting of docetaxel and trastuzumab that may be used in the treatment
of breast, esophageal and esophagogastric junction, and gastric cancers and salivary
gland tumors. Docetaxel every 21 days plus trastuzumab regimen may be used for the
treatment of breast cancer.;